ABSTRACT We previously reported early and extensive loss of astrocytic connexin 43 (Cx43) in acute demyelinating lesions of multiple sclerosis (MS) patients. Because it is widely accepted

that autoimmune T cells initiate MS lesions, we hypothesized that infiltrating T cells affect Cx43 expression in astrocytes, which contributes to MS lesion formation. Primary mixed glial

cell cultures were prepared from newborn mouse brains, and microglia were isolated by anti-CD11b antibody-conjugated magnetic beads. Next, we prepared astrocyte-rich cultures and

astrocyte/microglia-mixed cultures. Treatment of primary mixed glial cell cultures with interferon (IFN) γ, interleukin (IL)-4, or IL-17 showed that only IFNγ or IL-17 at high concentrations

protein levels in astrocyte-rich cultures. Finally, we confirmed that Th1 cell-conditioned medium decreased Cx43 protein levels in mixed glial cell cultures. These findings suggest that Th1

cell-derived IFNγ activates microglia to release IL-1β that reduces Cx43 gap junctions in astrocytes. Thus, Th1-dominant inflammatory states disrupt astrocytic intercellular communication

and may exacerbate MS. SIMILAR CONTENT BEING VIEWED BY OTHERS MYELIN OLIGODENDROCYTE GLYCOPROTEIN REACTIVE TH17 CELLS DRIVE JANUS KINASE 1 DEPENDENT TRANSCRIPTIONAL REPROGRAMMING IN

ASTROCYTES AND ALTER CELL SURFACE CYTOKINE RECEPTOR PROFILES DURING EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS Article Open access 07 June 2024 PD-L1 POSITIVE ASTROCYTES ATTENUATE

INFLAMMATORY FUNCTIONS OF PD-1 POSITIVE MICROGLIA IN MODELS OF AUTOIMMUNE NEUROINFLAMMATION Article Open access 09 September 2023 INFILTRATING CD8+ T CELLS EXACERBATE ALZHEIMER’S DISEASE

PATHOLOGY IN A 3D HUMAN NEUROIMMUNE AXIS MODEL Article 24 August 2023 INTRODUCTION Connexins (Cxs) are a family of vertebrate proteins that form gap junction (GJ) channels, the major

intercellular channel that facilitates direct signalling between cytoplasmic compartments of adjacent cells. A GJ consists of a pair of hemichannels, each of which is a hexameric cluster of

Cxs. Various tissues and cell types exhibit characteristic Cx expression profiles. In the central nervous system (CNS), there are abundant GJs between adjacent astrocytes (A/A junctions) and

between oligodendrocytes and astrocytes (O/A junctions)1,2,3. Astrocytes are functionally coupled to adjacent astrocytes and oligodendrocytes by GJs and form the “glial syncytium” that

maintains the homeostasis of glial and neuronal cells4. Cx43 is regarded as the primary astrocytic GJ protein5,6. Cx43 is diffusely expressed in the fine processes of cortical astrocytes in

grey matter7. In white matter, Cx43 expression levels are lower than in grey matter, and Cx43 is present in the foot processes of perivascular astrocytes7,8,9. Multiple sclerosis (MS) is an

inflammatory demyelinating disease of the CNS. The pathological hallmark of MS is demyelinating plaques with relatively preserved axons, suggesting that autoimmune responses preferentially

target CNS myelin. We previously reported early and extensive loss of astrocytic Cx43 in active white matter lesions of MS, neuromyelitis optica (NMO), and Baló’s concentric sclerosis (BCS)

pateints10,11,12. It has been suggested that early disruption of cell-to-cell communications among glial cells may have a crucial role in the development of demyelinating plaques12,13,14.

Perivascular lymphocytic cuffing mainly consisting of T cells has been observed significantly more frequently in active demyelinating lesions with Cx43 loss11. Moreover, Cx43 loss is

significantly associated with a rapidly progressive disease course, culminating in death11. Although some proinflammatory factors have been reported to reduce astrocytic expression of Cx43

_in vitro_15, the mechanisms of Cx43 loss remain to be elucidated in demyelinating diseases. Because it is widely accepted that autoimmune T cells are involved in the pathogenesis of MS and

experimental autoimmune encephalomyelitis (EAE), an animal model of MS16, we hypothesized that infiltrating T cells might alter Cx43 protein levels in astrocytes and contribute to MS lesion

extension. In this study, we investigated whether CD4+ T cells, such as T helper (Th) 1, Th17, or regulatory T (Treg) cells, directly or indirectly influence Cx43 protein levels in

astrocytes using a primary glial cell culture system. RESULTS CELL TYPES IN MIXED OR PURIFIED GLIAL CELL CULTURES Primary mixed glial cell cultures were prepared from the brains of newborn

C57BL/6 J mice. Primary mixed glial cell cultures contained 36.6 ± 11.1% ionized calcium-binding adapter molecule-1 (Iba-1)-positive microglia (five independent experiments), and the

remaining cells were almost all glial fibrillary acidic protein (GFAP)-positive astrocytes (Supplementary Fig. S1a). We detected Cx43 on the surface of astrocytes by immunocytochemistry

(Supplementary Fig. S1b). Cx30 was not detected in these cultures (Supplementary Fig. S1c). Microglia were isolated from these primary mixed glial cell cultures by anti-CD11b antibody

(Ab)-conjugated magnetic beads. Microglial cultures contained >90% Iba-1-positive cells (94.6 ± 2.8%, five independent experiments) (Supplementary Fig. S1d). Next, we prepared

astrocyte-rich cultures and astrocyte/microglia-mixed cultures (Supplementary Fig. S1e–f). Astrocyte-rich cultures contained <2% Iba-1-positive cells (0.7 ± 0.7%, nine independent

experiments). Astrocyte/microglia-mixed cultures contained 38.2 ± 2.1% (five independent experiments) Iba-1-positive cells when they were used for the following experiments. All of these

cultures contained no NeuN-positive cells (neurons), <1% Nogo-A-positive cells (oligodendrocytes), and <1% neuron-glial antigen 2 (NG2)-positive cells (oligodendrocyte precursors)

(Supplementary Fig. S1g–i). INTERFERON (IFN) Γ DOWNREGULATES CX43 PROTEIN LEVELS IN MIXED GLIAL CELL CULTURES Primary mixed glial cell cultures were treated with recombinant mouse IFNγ,

interleukin (IL)-4, and IL-17, which are produced mainly by Th1, Th2, and Th17 cells, respectively, at concentrations of 0 (control), 5, 50, or 500 ng/ml for 24 h. Western blotting revealed

that IFNγ reduced Cx43 protein levels in a dose-dependent manner, and that IL-17 at the highest concentration only (500 ng/ml) reduced Cx43 protein levels, whereas IL-4 did not affect Cx43

protein levels at any tested concentration (Fig. 1). IFNΓ DECREASES ASTROCYTIC CX43 PROTEIN AND MRNA LEVELS ONLY IN THE PRESENCE OF MICROGLIA Because primary mixed glial cell cultures

contained mainly astrocytes and microglia, we next examined whether IFNγ reduced Cx43 protein and mRNA levels in astrocytes directly or via microglia. Upon treatment of astrocyte-rich

cultures with IFNγ for 24 h, the protein and mRNA levels of Cx43 were unchanged (Fig. 2a,c,e). In contrast, Upon treatment of astrocyte/microglia-mixed cultures with IFNγ for 24 h, the

reduction of Cx43 protein and mRNA levels was dose dependent (Fig. 2b,d,f). Upon treatment of astrocyte-rich cultures and astrocyte/microglia-mixed cultures with IL-17 for 24 h, only the

highest concentration of IL-17 reduced the protein levels of Cx43 in astrocyte/microglia-mixed cultures, but not in astrocyte-rich cultures (Fig. 3). These observations implied that both

IFNγ and IL-17 reduced Cx43 protein and mRNA levels in astrocytes via microglia. Because IL-17 only affected Cx43 protein levels at extremely high concentrations, we focused on the effects

of IFNγ on glial cells in the following experiments. MICROGLIA ACTIVATED BY IFNΓ SUPPRESS THE FUNCTION OF GJS IN ASTROCYTES We next assessed the functional states of GJs using a scrape

loading/dye transfer (SLDT) assay. Upon treatment of astrocyte-rich cultures and astrocyte/microglia-mixed cultures with IFNγ for 24 h, the functions of GJs were significantly suppressed in

astrocyte/microglia-mixed cultures, but not in astrocyte-rich cultures (Fig. 4). HUMOURAL FACTORS SECRETED FROM IFNΓ-ACTIVATED MICROGLIA DECREASE CX43 PROTEIN LEVELS IN ASTROCYTES Next,

microglial cultures were treated with IFNγ and their supernatants were collected after 24 h (IFNγ-treated microglia-conditioned media). Resting microglia had a rod shape, whereas

IFNγ-treated microglia showed morphological changes including a large and round, amoeboid shape (Supplementary Fig. S2). When IFNγ-treated microglia-conditioned media were applied to

astrocyte-rich cultures, astrocytic Cx43 protein levels were significantly downregulated after 24 h (Fig. 5). These findings suggest that IFNγ activates microglia, and that humoural factors

secreted from activated microglia decrease Cx43 protein levels in astrocytes. IDENTIFICATION OF HUMOURAL FACTORS THAT DECREASE CX43 PROTEIN LEVELS IN ASTROCYTES To identify the humoural

factors secreted from activated microglia, we focused on several cytokines and chemokines, and measured their concentrations in IFNγ-treated microglia-conditioned media using a Bio-Plex

Multiplex System. IFNγ treatment significantly enhanced microglial secretion of all measured cytokines and chemokines in a dose-dependent manner (Fig. 6 and Supplementary Fig. S3). In

particular, we focused on IL-1β, IL-6, and tumour necrosis factor (TNF) α that were present in IFNγ-treated microglia-conditioned media at high concentrations (peak values: >100 pg/ml)

and have been reported as representative proinflammatory cytokines secreted from activated microglia17,18,19. We treated astrocyte-rich cultures with either IL-1β, IL-6, or TNFα for 24 h.

IL-1β significantly reduced Cx43 protein levels in astrocytes in a dose-dependent manner (Fig. 7a, Supplementary Fig. S4). However, upon treatment of astrocyte-rich cultures with

combinations of these cytokines, not only IL-1β and IL-6 or TNFα, but also IL-6 and TNFα reduced astrocytic Cx43 protein levels, although IL-6 or TNFα alone did not change Cx43 protein

levels (Fig. 7b). Therefore, the main humoural factor secreted from microglia, which decreases Cx43 protein levels in astrocytes, is IL-1β, whereas only IL-6 and TNFα in combination

decreases astrocytic Cx43 protein levels. CULTURE SUPERNATANTS OF TH1 CELLS DOWNREGULATE CX43 PROTEIN LEVELS IN MIXED GLIAL CELL CULTURES Next, we examined whether Th1 cells reduced Cx43

protein levels in mixed glial cell cultures. Stocks of conditioned media from Th1, Th17, and Treg cells differentiated from naïve T cells _in vitro_ contained 444.6, 0.1, and 3.2 ng/ml IFNγ,

respectively, as measured by enzyme-linked immunosorbent assay (ELISA). IFNγ was not detected in glial medium (GM) or complete RPMI medium. Primary mixed glial cell cultures were treated

with conditioned media from individual T cell subsets for 24 h, and then changes in Cx43 protein levels were quantified by western blotting. As shown in Fig. 8, only Th1 cell-conditioned

medium significantly reduced Cx43 protein levels in astrocytes (_p_ = 0.0038). These findings suggest that IFNγ derived from Th1 cells activates microglia to release IL-1β, the main factor

in the reduction of Cx43 protein levels in astrocytes. DISCUSSION In this study, we demonstrated that IFNγ activated microglia to release IL-1β that reduced astrocytic Cx43 mRNA and protein

levels, and functionally inhibited GJs in astrocytes. Although IL-1β secreted from microglia activated by IFNγ appeared to be the main factor in the reduction of Cx43 in astrocytes, other

proinflammatory cytokines in concert, such as TNFα and IL-6, also reduced Cx43. Significant downregulation of astrocytic Cx43 was also induced by humoural factors secreted from Th1 cells,

particularly IFNγ. Unexpectedly, high concentrations of IL-17 also diminished Cx43 protein levels in astrocytes, but only in the presence of microglia. It was previously reported that

functionally coupled astroglial cells determined by a dye injection method are decreased in astrocyte/microglia cocultures from newborn rat brains in the presence of 5% microglia following

administration of either TNFα, IL-1β, or IFNγ20. However, it was unclear which cytokines were mainly responsible for Cx43 down-modulation and whether these cytokines acted directly or

indirectly on astrocytes. In the present study, we clearly demonstrated that IFNγ indirectly decreased astrocytic Cx43 protein levels through activation of microglia and the subsequent

release of IL-1β. Our findings are consistent with a previous study showing that humoural factors secreted from microglia activated by lipopolysaccharide (LPS) stimulation reduce Cx43

expression in astrocytes18. Although IL-1β and TNFα secreted from LPS-stimulated microglia have been reported to be the main factors that inhibit Cx43 expression and functions of GJs in

astrocytes18, in our study, IL-1β alone decreased Cx43 protein levels and TNFα had no additional effect on the Cx43 protein reduction induced by IL-1β treatment. These data are in accordance

with previous studies that reported IL-1β downregulates the expression of Cx43 in astrocyte-rich cultures21,22. However, our present data differ from previous reports regarding the effects

of proinflammatory cytokines on glial cells23,24. Haghikia _et al_. reported that TNFα inhibits the function of GJs in astrocyte/microglia co-cultures containing 5% microglia derived from

rat brain23. Zhang _et al_. reported that IFNγ and TNFα, but not IL-1β, directly reduce Cx43 expression and suppress the function of GJs in newborn rat-derived spinal astrocyte cultures, in

which microglia were removed by shaking off, and >95% of the remaining cells were positive for GFAP24. In accordance with a previous report25, we also found that the shaking-off method

alone was insufficient to fully remove microglial cells, as determined by Iba-1 staining. Therefore, we believe that microglia should be isolated from mixed glial cell cultures using

anti-CD11b antibody-conjugated magnetic beads to purify astrocytes maximally26,27, and that differences in microglial removal methods may be partly responsible for the discrepancy among

studies. Differences in animal species, cell sources, and culture conditions might also be causes for the inconsistency, because astrocytes demonstrate inter-species and regional

morphological, molecular, and physiological heterogeneity28,29. Our study indicates that decreased Cx43 protein levels in astrocytes were in part attributable to a reduction of Cx43 mRNA

transcription caused by IFNγ-activated microglia. The detailed intracellular signalling pathway that regulates Cx43 expression remains to be elucidated in astrocytes. Recently, intracellular

signalling pathways, including c-Jun N-terminal kinase (JNK), nuclear factor-κB (NF-κB), and phosphatidylinositol 3-kinase, were reported to regulate the expression of Cx43 in

astrocytes24,30,31. In addition, the JNK-dependent ubiquitin-proteasome system was reported to be involved in regulating the protein levels of Cx43 through degradation31,32. Because IL-1β

activates JNK and NF-κB pathways in astrocytes33, the decrease in Cx43 protein levels might be partly caused by a reduction in Cx43 mRNA transcription through JNK and NF-κB pathways and

increased degradation by activation of the JNK pathway via IL-1β secreted from IFNγ-activated microglia. We and others have reported significant increases in IFNγ-producing T cells in the

cerebrospinal fluid (CSF) of MS patients, and the presence of IFNγ-positive lymphocytes in MS lesions34,35,36. Notably, IFNγ injection causes MS relapses37. IFNγ production also correlates

with exacerbation of neurological symptoms38. These findings indicate active involvement of IFNγ-producing Th1 cells in MS. However, the mechanisms of how these Th1 cells contribute to

demyelinating lesion formation are not completely resolved. How huge demyelinating lesions occasionally develop despite the presence of perivascular inflammatory cell infiltration occurring

in limited areas around vessels is also unclear. We previously reported extensive loss of Cx43 in MS and NMO lesions, and that cases with extensive Cx43 loss more frequently have a malignant

course culminating in death within 2 years after disease onset11. It is notable that astrocytic Cx43 expression is lost at the leading edges of concentric lesions in BCS patients, where

myelin and myelin proteins are preserved, including oligodendrocytic Cx32 and Cx4710. In EAE induced by myelin oligodendrocyte glycoprotein or myelin basic protein, diffuse loss of glial

Cxs, such as Cx32, Cx43, and Cx47, occurs in acute lesions39,40. Based on these observations, we propose that early loss of astrocytic Cx43 may lead to the formation of extensive

demyelinating lesions. This notion is supported by the fact that astrocytic Cx43/Cx30 double-knockout mice show widespread white matter pathologies including vacuolated oligodendrocytes,

intramyelinic oedema, loss of mature oligodendrocytes, and increased numbers of apoptotic cells41. Astrocytes form glial syncytia by coupling to adjacent astrocytes and oligodendrocytes via

Cx43 GJs. This process maintains homeostasis of the CNS4. Therefore, early loss of astrocytic Cx43 may promote oligodendrocyte apoptosis by disrupting glial syncytia, resulting in secondary

demyelination. Furthermore, the absence of astroglial Cx43/Cx30 weakens blood-brain barrier integrity42. Intriguingly, Boulay _et al_. recently reported that astroglial Cx43 controls immune

cell recruitment43. Thus, downregulation of astrocytic Cx43 may promote infiltration of immune cells into brain parenchyma and propagate inflammatory reactions, especially in the presence of

proinflammatory cytokines and chemokines produced by activated microglia, as shown by the current and previous studies44,45. Taken together, IFNγ-dominant inflammatory states might disrupt

astrocytic intercellular communication, which can lead to exacerbation of inflammation and extensive demyelination. In terms of IL-17, _IL17_ mRNA expression, the frequency of Th17 cells,

and IL-17 levels increase in the blood and CSF of MS patients46,47,48. Th17 cells are enriched in MS lesions49, and both Th17 cells and IL-17 have a pivotal role in the pathogenesis of

EAE50,51. It is interesting that high IL-17 concentrations downregulated the Cx43 protein levels of astrocytes in coculture with microglia in our study. Thus, Th17 cells may also contribute

to Cx43 loss in the brain parenchyma where astrocytes and microglia may be exposed to high concentrations of IL-17 when in the close contact with infiltrated Th17 cells. It was recently

reported that two-thirds of CNS-infiltrating Th17 cells express IFNγ in EAE52,53, and that T cells secreting IL-17 alone or IL-17 and IFNγ infiltrate the CNS prior to the onset of clinical

symptoms of EAE, where they may mediate CNS inflammation through microglial activation54. It was also reported that IL-17+ IFNγ+ CD4+ T cells are abundant in MS lesions55. These IL-17 and

IFNγ double-positive cells are regarded as pathogenic Th17 cells that develop under a Th1-prone cytokine milieu and become ex-Th17 cells producing IFNγ but not IL-1756,57. Therefore, Th17

cells may also contribute to MS lesion formation via IFNγ that effectively reduces Cx43 expression in astrocytes. In conclusion, we propose that Th1 cell-derived humoural factors, mainly

IFNγ, induce microglial activation and the release of IL-1β that downregulates astrocytic Cx43, which might exacerbate the inflammatory processes in demyelinating disorders. Thus, IFNγ and

Th1-prone conditions are important targets to prevent development of extensive demyelinating lesions. METHODS ANIMALS All cultures were prepared using cells from C57BL/6 J mice (Charles

River Laboratories Japan, Inc., Yokohama, Japan). The protocols for animal experiments were reviewed and approved by the Committee of Ethics on Animal Experiments at Kyushu University

Faculty of Medicine (A25–196, A27–205). All animal experiments were performed in accordance with the Regulations for Animal Experiments defined by the Institutional Animal Care and Use

Committee at Kyushu University. GLIAL CELL CULTURES Primary mixed glial cell cultures were prepared from the brains of newborn C57BL/6 J mice according to a previously described method58.

Briefly, brains were removed under sterile conditions, and the meninges were carefully removed. The tissue was dissociated by passing through a nylon mesh in Hanks’ balanced salt solution

(HBSS; Sigma-Aldrich, Saint Louis, MO, USA) containing 50 U/ml penicillin and 50 μg/ml streptomycin (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) to prevent contamination. After

washing with HBSS, the cell suspension was plated in 75 cm2 culture flasks at a density of one to two brains per flask in 10 ml of GM. GM consisted of Dulbecco’s Modified Eagle’s Medium

(Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS) (Equitech-Bio, Kerrville, TX, USA), 5 μg/ml bovine insulin (Sigma-Aldrich), and 0.2% glucose. The cells were maintained at 37 

°C in a humidified atmosphere containing 5% CO2 with three medium changes in the first week and no medium change in the second week to induce the proliferation of microglia. At confluency

(12–15 days), mixed glial cells were detached by Accutase (Innovative Cell Technologies, San Diego, CA, USA) treatment and replated. After 5–10 days of culture, mixed glial cell cultures

that had reached 100% confluence were used for experiments. We also generated astrocyte-rich cultures and microglial cultures from primary mixed glial cell cultures using magnetic-activated

cell sorting (MACS, Miltenyi Biotec, Bergisch Gladbach, Germany). Mixed glial cell cultures were prepared as described above, and glial cells were detached by Accutase treatment at day

12–15. The cell suspension was washed and resuspended in 10 ml MACS Separation Buffer (Miltenyi Biotec). After filtration through a 70 μm pore filter, the cell suspension was centrifuged at

300 × _g_ for 5 min at 4 °C. Then, the cells were separated into CD11b-positive and -negative fractions using CD11b MicroBeads (microbeads conjugated to a monoclonal rat anti-mouse CD11b Ab;

Miltenyi Biotec) according to the manufacturer’s protocol with some modification26,27. Briefly, 1 × 107 cells were resuspended in 90 μl of separation buffer and 10 μl of CD11b MicroBeads,

and incubated at 4 °C for 30 min with gentle mixing every 10 min. Then, the cells were washed and resuspended in 500 μl of separation buffer per 1 × 108 cells. The cell suspension was

applied to an LS column (Miltenyi Biotec) fitted into the QuadroMACS™ cell separator (Miltenyi Biotec), and then the cells were separated into CD11b-negative and -positive fractions. The

astrocyte-enriched fraction (astrocyte-rich culture), corresponding to the CD11b-negative fraction, was resuspended in GM before plating. After 7–10 days, astrocyte-rich cultures that

reached 100% confluence were used for experiments. The CD11b-positive fraction containing microglia was plated in GM and used for experiments after 24 h (microglial culture). CD11b-negative

and -positive fractions were mixed at a ratio of 3:1 (astrocyte/microglia-mixed culture). After 7–10 days, mixed cultures that reached 100% confluence were used for experiments. HELPER T

CELL DIFFERENTIATION Spleens were aseptically removed from C57BL/6 J mice (8–10 weeks old), and splenocytes were dissociated into single cells. After red blood cell lysis, naïve CD4+ T cells

were isolated from the splenocytes using a Naïve CD4+ T Cell Isolation Kit (Miltenyi Biotec) according to the manufacturer’s protocol and suspended in complete RPMI medium [RPMI-1640 medium

supplemented with 2 mM L-glutamine (Sigma-Aldrich), 1 mM sodium pyruvate (Gibco, Thermo Fisher Scientific), 50 μM 2-mercaptoethanol, 50 U/ml penicillin, 50 μg/ml streptomycin, and 10% FBS

(Cell Culture Bioscience, Lenexa, KS, USA)]. Purified naïve CD4+ T cells (1 × 105 cells/well) were seeded in 96-well plates precoated with 5 μg/ml anti-CD3e Ab. The cells were cultured under

Th1 (20 ng/ml IL-2, 20 ng/ml IL-12, and 10 μg/ml anti-IL-4 Ab), Th17 [5 ng/ml transforming growth factor (TGF) β, 30 ng/ml IL-6, and 10 μg/ml anti-IFNγ Ab), or Treg (5 ng/ml TGFβ and 20 

ng/ml IL-2)-skewing conditions in 200 μl of complete RPMI medium with 2 μg/ml anti-CD28 Ab for 3 days. On day 3, differentiated T cells were collected and washed with complete RPMI medium.

Then, the cells were resuspended in complete RPMI medium at 5 × 105 cells/ml and reseeded with 2 μg/ml anti-CD28 Ab in 96-well plates precoated with anti-CD3e Ab for 24 h. On day 4, the T

cell culture supernatants were collected and stored at −80 °C before being used for treatment of glial cells. Recombinant mouse IL-2, IL-12, and TGFβ were purchased from R&D Systems

(Minneapolis, MN, USA). Recombinant mouse IL-6 was purchased from BioLegend (San Diego, CA, USA). No azide/low endotoxin-grade anti-IL-4 (clone 11B11, rat IgG1), anti-IFNγ (clone XMG1.2, rat

IgG1), anti-CD3e (clone 145-2C11, hamster IgG1), and anti-CD28 (clone 37.51, hamster IgG2) Abs were purchased from BD Biosciences (Franklin Lakes, NJ, USA). The purity and differentiation

state of naïve CD4+ T cells and differentiated T cells were confirmed by flow cytometry. Before staining, Th1 and Th17 cells were stimulated with 25 ng/ml phorbol 12-myristate 13-acetate

(Sigma-Aldrich) and 1 μg/ml ionomycin (Sigma-Aldrich) for 5 h, and 10 μg/ml brefeldin A (Sigma-Aldrich) was added for the last 4 h. T cells were washed and blocked with an anti-CD16/32 Ab.

Naïve CD4+ T cells were stained with anti-CD4 (clone RM4-5), anti-I-A/I-E, anti-CD44, and anti-CD62L Abs. Th1 and Th17 cells were stained with anti-CD4 (clone RM4-5) and anti-I-A/I-E Abs.

Treg cells were stained with anti-CD4 (clone GK1.5), anti-I-A/I-E, and anti-CD25 Abs. Differentiated T cells were fixed and permeabilized with Fixation buffer and Permeabilization Wash

Buffer (Sony Biotechnology, Champaign, IL, USA) for Th1 and Th17 cells or FOXP3 Fix/Perm buffer Set (Sony Biotechnology) for Treg cells, and then stained intracellularly (anti-IFNγ,

anti-IL-4, and anti-IL-17A Abs for Th1 and Th17 cells; anti-mouse/rat Foxp3 Ab for Treg cells). The cells were subsequently analysed by flow cytometry using a Cell Sorter SH-800 (Sony,

Tokyo, Japan). Detailed information of the Abs used in flow cytometry is listed in Supplementary Table S1. The purity of naïve CD4+ T cells (CD44loCD62+ cells) was typically 93% or higher.

Differentiated Th1 and Th17 cells predominantly expressed IFNγ and IL-17, respectively, but rarely expressed IL-4. Most Treg cells expressed both CD25 and Foxp3 (Supplementary Fig. S5).

TREATMENT OF GLIAL CELLS Mixed glial cell cultures, astrocyte-rich cultures, and astrocyte/microglia-mixed cultures were treated with recombinant mouse IFNγ, IL-4, and IL-17 (R&D

Systems) diluted in GM for 24 h. Astrocyte-rich cultures were treated with recombinant mouse IL-1β, IL-6 (BioLegend), and TNFα (R&D Systems) diluted in GM for 24 h. The concentrations of

these cytokines were 300 pg/ml for IL-1β, 1400 pg/ml for IL-6, and 1300 pg/ml for TNFα based on their concentrations in IFNγ-treated microglia-conditioned medium. Astrocyte-rich cultures

were also treated with 0, 180, 240 or 300 pg/ml recombinant mouse IL-1β for 24 h. The concentrations of IL-1β at 180 and 300 pg/ml were approximately equal to those of IL-1β in

microglia-conditioned media when microglia were treated with 50 or 500 ng/ml IFNγ for 24 h, respectively. Upon treatment of mixed glial cells with conditioned media from T cells, they were

diluted in GM at a ratio of 1:1, and treatments were performed for 24 h. WESTERN BLOTTING OF CX43 After all treatments of glial cells, the cells were solubilised in a

radioimmunoprecipitation assay buffer containing a protease inhibitor cocktail, 0.5% sodium dodecyl sulfate (Nacalai Tesque, Kyoto, Japan), and PhosSTOP phosphatase inhibitor cocktail (Roche

Diagnostics, Mannheim, Germany). The lysates were placed on ice for 30 min and then centrifuged at 4 °C for 10 min at 10,000 × _g_. Supernatants were collected, analysed for protein

concentrations using a BCA protein assay kit (Pierce, Thermo Fisher Scientific), and adjusted to equal protein concentrations. Laemmli’s buffer was added to the protein samples, followed by

boiling at 95 °C for 5 min. Equal amounts of protein were separated by 7.5–15% gradient poly-acrylamide gel (REAL GEL PLATE, Bio Craft, Tokyo, Japan) electrophoresis and blotted onto

polyvinyl difluoride membranes. The membranes were incubated with a blocking solution [Blocking One-P for Cx43 and Blocking One (Nacalai Tesque) for β-actin] and subsequently incubated with

an anti-Cx43 Ab (1:10,000; rabbit polyclonal IgG; Abcam, Cambridge, UK) overnight at 4 °C or with an anti-β-actin Ab (1:20,000; clone AC-15, mouse monoclonal IgG1; Sigma-Aldrich) for 1 h at

room temperature. After washing, the membranes were incubated with a horseradish peroxidase-conjugated secondary Ab for 1 h at room temperature. Then, the membranes were washed and

visualized by enhanced chemiluminescence (ECL Prime, GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Band intensities were measured using the ChemiDoc™ XRS system (Bio-Rad Laboratories,

Hercules, CA, USA) and normalized to β-actin levels. IMMUNOCYTOCHEMISTRY Glial cells plated on collagen type 1-coated 8-well culture slides (Corning, Corning, NY, USA) were washed with PBS,

fixed with 4% paraformaldehyde for 5 min, and permeabilised with 0.05% Triton X-100 in PBS (PBS-T) for 15 min. The cells were incubated with primary Abs against Cx43, Iba-1, GFAP, NeuN,

Nogo-A, or NG2 (detailed information of Abs are listed in Supplementary Table S2) in PBS-T with 5% goat serum for 1 h at 37 °C. After rinsing, the cells were incubated with Alexa 488- and

546- or 594-conjugated secondary Abs and 4′,6-diamidino-2-phenylindole (DAPI) for 30 min at 37 °C. Images were captured using a confocal laser microscope system (Nikon A1, Nikon, Tokyo,

Japan) with Plan-Apochromat 20 × (0.75 NA) or Plan-Apochromat 10 × (0.45 NA) objective (Nikon) or fluorescence microscope (BZ-X700, Keyence, Osaka, Japan) with Plan-Apochromat 20 × (0.75 NA)

or Plan-Fluor 10 × (0.30 NA) objective (Nikon). RNA EXTRACTION AND QUANTITATIVE REAL-TIME REVERSE TRANSCRIPTASE (RT)-PCR Total RNA was extracted from cells using an RNeasy Mini kit (Qiagen,

Venlo, Netherlands) following the manufacturer’s instructions. cDNA was synthesized using ReverTra Ace qPCR RT Master Mix with gDNA Remover (Toyobo, Osaka, Japan). Quantitative real-time

RT-PCR analysis of cDNAs was performed with an Applied Biosystems 7500 Real-Time PCR System (Applied Biosystems, Thermo Fisher Scientific) using TaqMan Gene Expression Master Mix and TaqMan

Gene Expression Assays (Cx43 (_Gja1_), Mm01179639_s1; Gapdh, Mm99999915_g1; Applied Biosystems, Thermo Fisher Scientific). Gapdh was used as an internal control gene. PCR cycling conditions

were 50 °C for 2 min, 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 sec and 60 °C for 1 min. The ΔΔCT efficiency corrected method was used to calculate relative mRNA levels. SLDT

ASSAY GJ permeability was determined at 37 °C using an SLDT assay as described previously59 with minor modifications. In brief, confluent glial cells in 12-well plates were washed with PBS

and scraped in the presence of PBS containing 0.1% of the fluorescent dye Lucifer yellow (molecular weight: 457.3 Da; Sigma-Aldrich) and 0.05% rhodamine B-dextran (molecular weight: 10,000 

Da; Molecular Probes, Thermo Fisher Scientific). After 2 min of incubation, the cells were washed three times with PBS and then incubated for an additional 5 min in PBS to allow the loaded

dye to transfer to adjoining cells. The cells were then fixed with 4% paraformaldehyde, counterstained with Hoechst 33342, and observed under a fluorescence microscope. Damaged cells absorb

the dye mixture and transfer Lucifer yellow into neighbouring cells through functional GJs. In contrast, rhodamine B-dextran does not pass through GJ and is restricted to the initially

loaded cells. Dye diffusion was captured using fluorescence microscope (BZ-X700, Keyence) with Plan-Fluor 10 × (0.30 NA) objective (Nikon), and quantified by measuring fluorescent areas.

Quantification of the function of GJs was performed by subtraction of the rhodamine B-positive fluorescent area from the Lucifer yellow-positive fluorescent area by ImageJ software (US

National Institutes of Health, Bethesda, MD, USA). ELISA The levels of IFNγ in culture supernatants were measured by an ELISA kit (Quantikine® ELISA Mouse IFN-γ Immunoassay; R&D systems)

according to the manufacturer’s instructions. MULTIPLEXED FLUORESCENT BEAD-BASED IMMUNOASSAY IFNγ-treated microglia-conditioned media were collected and analysed simultaneously for 23

cytokines and chemokines: IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-17A, TNFα, granulocyte-colony stimulating factor,

granulocyte-macrophage colony-stimulating factor, IFNγ, chemokine (C-X-C motif) ligand 1 (KC), chemokine (C-C motif) ligand (CCL) 2 (monocyte chemoattractant protein 1), CCL3 [Macrophage

inflammatory protein (MIP)-1α], CCL4 (MIP-1β), CCL5 (RANTES), and CCL11 (eotaxin) by a Bio-Plex Multiplex System (Bio-Rad Laboratories) according to the manufacturer’s instructions36. All

samples were analysed undiluted in duplicate. STATISTICAL ANALYSIS Data are expressed as the mean ± standard deviation (s.d.) of at least four experiments. One-way analysis of variance

(ANOVA) followed by a Dunnett’s multiple comparison test were used to analyse data. All analyses were carried out using JMP® Pro version 11.0.0 software (SAS Institute, Cary, NC, USA). The

significance level was set at _p_ < 0.05. ADDITIONAL INFORMATION HOW TO CITE THIS ARTICLE: Watanabe, M. _et al_. Th1 cells downregulate connexin 43 gap junctions in astrocytes via

microglial activation. _Sci. Rep._ 6, 38387; doi: 10.1038/srep38387 (2016). PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and

institutional affiliations. REFERENCES * Massa, P. T. & Mugnaini, E. Cell junctions and intramembrane particles of astrocytes and oligodendrocytes: a freeze-fracture study. Neuroscience.

7, 523–538 (1982). CAS  Google Scholar  * Rash, J. E., Yasumura, T., Dudek, F. E. & Nagy, J. I. Cell specific expression of connexins and evidence of restricted gap junctional coupling

between glial cells and between neurons. J. Neurosci. 21, 1983–2000 (2001). CAS  PubMed  PubMed Central  Google Scholar  * Takeuchi, H. & Suzumura, A. Gap junctions and hemichannels

composed of connexins: potential therapeutic targets for neurodegenerative diseases. Front. Cell. Neurosci. 8, 189 (2014). PubMed  PubMed Central  Google Scholar  * Orthmann-Murphy, J. L.,

Abrams, C. K. & Scherer, S. S. Gap junctions couple astrocytes and oligodendrocytes. J. Mol. Neurosci. 35, 101–116 (2008). CAS  PubMed  PubMed Central  Google Scholar  * Dermietzel, R.,

Hertberg, E. L., Kessler, J. A. & Spray, D. C. Gap junctions between cultured astrocytes: immunocytochemical, molecular, and electrophysiological analysis. J. Neurosci. 11, 1421–1432

(1991). CAS  Google Scholar  * Giaume, C. et al. Gap junctions in cultured astrocytes: single-channel currents and characterization of channel-forming protein. Neuron. 6, 133–143 (1991). CAS

  Google Scholar  * Yamamoto, T., Ochalski, A., Hertzberg, E. L. & Nagy, J. I. LM and EM immunolocalization of the gap junctional protein connexin 43 in rat brain. Brain Res. 508,

313–319 (1990). CAS  Google Scholar  * Simard, M., Arcuino, G., Takano, T., Liu, Q. S. & Nedergaard, M. Signaling at the gliovascular interface. J. Neurosci. 23, 9254–9262 (2003). CAS 

PubMed  PubMed Central  Google Scholar  * Altevogt, B. M. & Paul, D. L. Four classes of intercellular channels between glial cells in the CNS. J. Neurosci. 24, 4313–4323 (2004). CAS 

PubMed  PubMed Central  Google Scholar  * Masaki, K. et al. Extensive loss of connexins in Baló’s disease: evidence for an auto-antibody-independent astrocytopathy via impaired

astrocyteoligodendrocyte/myelin interaction. Acta Neuropathol. 123, 887–900 (2012). Google Scholar  * Masaki, K. et al. Connexin 43 astrocytopathy linked to rapidly progressive multiple

sclerosis and neuromyelitis optica. PLoS One. 8, e72919 (2013). ADS  CAS  PubMed  PubMed Central  Google Scholar  * Masaki, K. Connexin pathology in acute multiple sclerosis, Baló’s disease

and neuromyelitis optica. Clin. Exp. Neuroimmmunol. 4, 36–44 (2013). Google Scholar  * Kira, J. Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis: astrocytopathy as a

common denominator in demyelinating disorders. J. Neurol. Sci. 311, 69–77 (2011). CAS  Google Scholar  * Masaki, K. Early disruption of glial communication via connexin gap junction in

multiple sclerosis, Baló’s disease and neuromyelitis optica. Neuropathology. 35, 469–480 (2015). CAS  Google Scholar  * Orellana, J. A., Martinez, A. D. & Retamal, M. A. Gap junction

channels and hemichannels in the CNS: regulation by signaling molecules. Neuropharmacology. 75, 567–582 (2013). CAS  Google Scholar  * Sospedra, M. & Martin, R. Immunology of multiple

sclerosis. Annu. Rev. Immunol. 23, 683–747 (2005). CAS  Google Scholar  * Aloisi, F. Immune function of microglia. Glia. 36, 165–179 (2001). CAS  Google Scholar  * Même, W. et al.

Proinflammatory cytokines released from microglia inhibit gap junctions in astrocytes: potentiation by β-amyloid. FASEB J. 20, 494–496 (2006). Google Scholar  * Franco, R. &

Fernández-Suárez, D. Alternatively activated microglia and macrophages in the central nervous system. Prog. Neurobiol. 131, 65–86 (2015). CAS  Google Scholar  * Hinkerohe, D. et al. Effects

of cytokines on microglial phenotypes and astroglial coupling in an inflammatory coculture model. Glia. 52, 85–97 (2005). Google Scholar  * John, G. R. et al. IL-1β differentially regulates

calcium wave propagation between primary human fetal astrocytes via pathways involving P2 receptors and gap junction channels. Proc. Natl. Acad. Sci. USA 96, 11613–11618 (1999). ADS  CAS 

Google Scholar  * Zeis, T. et al. Metabolic gene expression changes in astrocytes in Multiple Sclerosis cerebral cortex are indicative of immune-mediated signaling. Brain Behav. Immun. 48,

313–325 (2015). CAS  Google Scholar  * Haghikia, A. et al. Intracellular application of TNF-alpha impairs cell to cell communication via gap junctions in glioma cells. J. Neurooncol. 86,

143–152 (2008). CAS  Google Scholar  * Zhang, F. F., Morioka, N., Nakashima-Hisaoka, K. & Nakata, Y. Spinal astrocytes stimulated by tumor necrosis factor-α and/or interferon-γ attenuate

connexin 43-gap junction via c-jun terminal kinase activity. J. Neurosci. Res. 91, 745–756 (2013). CAS  Google Scholar  * Saura. J. Microglial cells in astroglial cultures: a cautionary

note. J. Neuroinflammation. 4, 26 (2007). PubMed  PubMed Central  Google Scholar  * Marek, R., Caruso, M., Rostami, A., Grinspan, J. B. & Das Sarma, J. Magnetic cell sorting: a fast and

effective method of concurrent isolation of high purity viable astrocytes and microglia from neonatal mouse brain tissue. J. Neurosci. Methods. 175, 108–118 (2008). Google Scholar  *

Losciuto, S. et al. An efficient method to limit microglia-dependent effects in astroglial cultures. J. Neurosci. Methods. 207, 59–71 (2012). CAS  Google Scholar  * Oberheim, N. A., Goldman,

S. A. & Nedergaard, M. Heterogeneity of astrocytic form and function. Methods Mol. Biol. 814, 23–45 (2012). CAS  PubMed  PubMed Central  Google Scholar  * Theis, M. & Giaume, C.

Connexin-based intercellular communication and astrocyte heterogeneity. Brain Res. 1487, 88–98 (2012). CAS  Google Scholar  * Zhao, Y., Rivieccio, M. A., Lutz, S., Scemes, E. & Brosnan,

C. F. The TLR3 ligand polyI: C downregulates connexin 43 expression and function in astrocytes by a mechanism involving the NF-κB and PI3 kinase pathways. Glia. 54, 775–785 (2006). PubMed 

PubMed Central  Google Scholar  * Liao, C. K., Jeng, C. J., Wang, H. S., Wang, S. H. & Wu, J. C. Lipopolysaccharide induces degradation of connexin43 in rat astrocytes via the

ubiquitin-proteasome proteolytic pathway. PLoS One. 8, e79350 (2013). ADS  PubMed  PubMed Central  Google Scholar  * Zhang, F. F., Morioka, N., Kitamura, T., Hisaoka-Nakashima, K. &

Nakata, Y. Proinflammatory cytokines downregulate connexin 43-gap junctions via the ubiquitin-proteasome system in rat spinal astrocytes. Biochem. Biophys. Res. Commun. 464, 1202–1208

(2015). CAS  Google Scholar  * Wu, C. Y., Hsieh, H. L., Jou, M. J. & Yang, C. M. Involvement of p42/p44 MAPK, p38 MAPK, JNK and nuclear factor-kappa B in interleukin-1β-induced matrix

metalloproteinase-9 expression in rat brain astrocytes. J. Neurochem. 90, 1477–1488 (2004). CAS  Google Scholar  * Traugott, U. & Lebon, P. Multiple sclerosis: involvement of interferons

in lesion pathogenesis. Ann. Neurol. 24, 243–251 (1988). CAS  Google Scholar  * Olsson, T. et al. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of

interferon-gamma. J. Clin. Invest. 86, 981–985 (1990). CAS  PubMed  PubMed Central  Google Scholar  * Ishizu, T. et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal

multiple sclerosis. Brain. 128, 988–1002 (2005). Google Scholar  * Panitch, H. S., Hirsch, R. L., Haley, A. S. & Johnson, K. P. Exacerbations of multiple sclerosis in patients treated

with gamma interferon. Lancet. 329, 893–895 (1987). Google Scholar  * Petereit, H. F., Richter, N., Pukrop, R. & Bamborschke, S. Interferon gamma production in blood lymphocytes

correlates with disability score in multiple sclerosis patients. Mult. Scler. 6, 19–23 (2000). CAS  Google Scholar  * Brand-Schieber, E. et al. Connexin43, the major gap junction protein of

astrocytes, is down-regulated in inflamed white matter in an animal model of multiple sclerosis. J. Neurosci. Res. 80, 798–808 (2005). CAS  PubMed  PubMed Central  Google Scholar  *

Markoullis, K. et al. Disruption of oligodendrocyte gap junctions in experimental autoimmune encephalomyelitis. Glia. 60, 1053–1066 (2012). Google Scholar  * Lutz, S. E. et al. Deletion of

astrocyte connexins 43 and 30 leads to a dysmyelinating phenotype and hippocampal CA1 vacuolation. J. Neurosci. 29, 7743–7752 (2009). CAS  PubMed  PubMed Central  Google Scholar  * Ezan, P.

et al. Deletion of astroglial connexins weakens the blood-brain barrier. J. Cereb. Blood Flow Metab. 32, 1457–1467 (2012). CAS  PubMed  PubMed Central  Google Scholar  * Boulay, A. C. et al.

Immune quiescence of the brain is set by astroglial connexin 43. J. Neurosci. 35, 4427–4439 (2015). CAS  PubMed  PubMed Central  Google Scholar  * Zhang, G. X., Baker, C. M., Kolson, D. L.

& Rostami, A. M. Chemokines and chemokine receptors in the pathogenesis of multiple sclerosis. Mult. Scler. 6, 3–13 (2000). CAS  Google Scholar  * Yamasaki, R. et al. Differential roles

of microglia and monocytes in the inflamed central nervous system. J. Exp. Med. 211, 1533–1549 (2014). CAS  PubMed  PubMed Central  Google Scholar  * Matusevicius, D. et al. Interleukin-17

mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult. Scler. 5, 101–104 (1999). CAS  Google Scholar  * Brucklacher-Waldert, V., Stuerner, K., Kolster,

M., Wolthausen, J. & Tolosa, E. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain. 132, 3329–3341 (2009). Google Scholar  * Wen, S. R. et al.

Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 244, 94–96 (2012). CAS  Google Scholar  * Tzartos, J. S.

Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 172, 146–155 (2008). CAS 

PubMed  PubMed Central  Google Scholar  * Cua, D. J. et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 421, 744–748

(2003). ADS  CAS  Google Scholar  * Langrish, C. L. et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233–240 (2005). CAS  PubMed 

PubMed Central  Google Scholar  * Kurschus, F. C. et al. Genetic proof for the transient nature of the Th17 phenotype. Eur. J. Immunol. 40, 3336–3346 (2010). CAS  Google Scholar  * Hirota,

K. et al. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat. Immunol. 12, 255–263 (2011). CAS  PubMed  PubMed Central  Google Scholar  * Murphy, A. C., Lalor, S. J.,

Lynch, M. A. & Mills, K. H. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav. Immun.

24, 641–651 (2010). CAS  Google Scholar  * Kebir, H. et al. Preferential recruitment of interferon-γ-expressing TH17 cells in multiple sclerosis. Ann. Neurol. 66, 390–402 (2009). ADS  CAS 

Google Scholar  * Lee, Y. K. et al. Late developmental plasticity in the T helper 17 lineage. Immunity. 30, 92–107 (2009). CAS  PubMed  PubMed Central  Google Scholar  * Annunziato, F. &

Romagnani, S. The transient nature of the Th17 phenotype. Eur. J. Immunol. 40, 3312–3316 (2010). CAS  Google Scholar  * Suzumura, A., Bhat, S., Eccleston, P. A., Lisak, R. P. &

Silberberg, D. H. The isolation and long-term culture of oligodendrocytes from newborn mouse brain. Brain. Res. 324, 379–383 (1984). CAS  Google Scholar  * el-Fouly, M. H., Trosko, J. E.

& Chang, C. C. Scrape-loading and dye transfer. A rapid and simple technique to study gap junctional intercellular communication. Exp. Cell Res. 168, 422–430 (1987). CAS  Google Scholar

  Download references ACKNOWLEDGEMENTS This study was supported in part by a Health and Labour Sciences Research Grant on Intractable Diseases (H26-Nanchitou (Nan)-Ippan-074) from the

Ministry of Health, Labour, and Welfare, Japan, the Practical Research Project for Rare/Intractable Diseases from Japan Agency for Medical Research and Development (AMED), a “Glial assembly”

Grant-in-Aid for Scientific Research on Innovative Areas (MEXT KAKENHI Grant Numbers 25117001 and 25117012) from the Ministry of Education, Culture, Sports, Science and Technology of Japan,

a Grant-in-Aid for Scientific Research (A) (JSPS KAKENHI Grant Number 16H02657), a Grant-in-Aid for Scientific Research (C) (JSPS KAKENHI Grant Numbers 16K09694 and 26461295), a

Grant-in-Aid for Exploratory Research (JSPS KAKENHI Grant Number 15K15341), and a Grant-in-Aid for Young Scientists (B) (JSPS KAKENHI Grant Number 15K19489) from the Japan Society for the

Promotion of Science. We appreciate the assistance from The Research Support Center, Research Center for Human Disease Modeling, Kyushu University Graduate School of Medical Sciences. AUTHOR

INFORMATION AUTHORS AND AFFILIATIONS * Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan Mitsuru Watanabe, 

Katsuhisa Masaki, Ryo Yamasaki, Takuya Matsushita & Jun-ichi Kira * Department of Neuroimmunology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, 464-8601,

Japan Jun Kawanokuchi, Hideyuki Takeuchi & Akio Suzumura * Institute of Traditional Chinese Medicine, Suzuka University of Medical Science, Suzuka, 510-0226, Japan Jun Kawanokuchi *

Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama, 236-0004, Japan Hideyuki Takeuchi Authors * Mitsuru Watanabe View author

publications You can also search for this author inPubMed Google Scholar * Katsuhisa Masaki View author publications You can also search for this author inPubMed Google Scholar * Ryo

Yamasaki View author publications You can also search for this author inPubMed Google Scholar * Jun Kawanokuchi View author publications You can also search for this author inPubMed Google

Scholar * Hideyuki Takeuchi View author publications You can also search for this author inPubMed Google Scholar * Takuya Matsushita View author publications You can also search for this

author inPubMed Google Scholar * Akio Suzumura View author publications You can also search for this author inPubMed Google Scholar * Jun-ichi Kira View author publications You can also

search for this author inPubMed Google Scholar CONTRIBUTIONS M.W. and J. Kira conceived the experiments. All authors contributed to the experimental design. M.W. performed the experiments

and analysed the results. J. Kawanokuchi, H.T., and A.S. provided technical advice for the experiments. M.W., K.M., R.Y., T.M., and J. Kira were involved in the interpretation of results.

M.W., K.M., and J. Kira drafted the manuscript. All authors reviewed the manuscript. ETHICS DECLARATIONS COMPETING INTERESTS T.M. has received honoraria from Bayer Schering Pharma, Biogen

Idec, Takeda Pharmaceutical Company, and Mitsubishi Tanabe Pharma; J. Kira is a consultant for Biogen Idec Japan, Novartis Pharma A.G., and Medical Review. He has received speaking fees

and/or honoraria from Bayer Healthcare, Mitsubishi Tanabe Pharma, Nobelpharma, Otsuka Pharmaceutical, Novartis Pharma K.K., Takeda Pharmaceutical Company, Nippon Rinsho, and Medical Review.

He has received grants from Pfizer, Eizai, Japan Blood Products Organization, Mitsubishi Tanabe Pharma, and Bayer Healthcare; the other authors declare no conflicts of interest. ELECTRONIC

SUPPLEMENTARY MATERIAL SUPPLEMENTARY INFORMATION RIGHTS AND PERMISSIONS This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party

material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons

license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ Reprints

and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Watanabe, M., Masaki, K., Yamasaki, R. _et al._ Th1 cells downregulate connexin 43 gap junctions in astrocytes via microglial activation.

_Sci Rep_ 6, 38387 (2016). https://doi.org/10.1038/srep38387 Download citation * Received: 14 July 2016 * Accepted: 08 November 2016 * Published: 08 December 2016 * DOI:

https://doi.org/10.1038/srep38387 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently

available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative